MedTrace Logo

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

NCT01187199 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2026-04-16

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.

Conditions

Interventions

DRUG

Temsirolimus

Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.

DRUG

Bevacizumab

Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.

DRUG

Paclitaxel

Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.

DRUG

Sorafenib

Starting dose 200 mg by mouth daily for a 21 day cycle.

DRUG

Carboplatin

Starting dose AUC 2 by vein on day 1 of a 21 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Shannon Westin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-19
Primary Completion
2026-04-30
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187199 on ClinicalTrials.gov